Skip to main content
SpringerLink
Log in

Interferon-α-n3

Alferon, Alferon LDO®, Alferon N®, Alferon N Gel®, Altemol®, Natural α interferon, α-n3-IF

  • Section 2: Depatitis C
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Simon DM, Gordon SC, Kaplan MM, et al. Treatment of chronic hepatitis C with interferon alfa-n3: amulticenter, randomized, open-label trial. Hepatology 1997 Feb; 25: 445–8

    Article  PubMed  CAS  Google Scholar 

  2. Sostegni R, Ghissetti V, Pittaluga F, et al. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998 Aug; 28: 341–6

    Article  PubMed  CAS  Google Scholar 

  3. Ascione A, De Luca M, Guardascione MA, et al. Recombinant vs leucocytic interferon in the treatment of HCV chronic liver disease: final report of a randomized controlled trial. J Hepatol 1998; 28 Suppl. 1: 191

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Interferon-α-n3. Drugs R&D 2, 271–273 (1999). https://doi.org/10.2165/00126839-199902040-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902040-00013

Keywords

Search

Navigation